Latest Product Launches News

Firebrick Pharma has introduced its Nasodine Throat Spray in Singapore, marking its first international product launch and setting the stage for further global rollouts in 2026.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

City Chic Collective reports a robust 71% rise in underlying EBITDA for the first half of FY26, powered by strong ANZ revenue growth and strategic inventory management in the US despite tariff headwinds.

Wellnex Life reports a $2.4 million EBITDA improvement in H1 FY26 and reaches breakeven by Q2, supported by strong Pain Away sales and expanded distribution.

Kinatico Limited has reported a robust 42% increase in its SaaS revenue for Q2FY26, driven by strong operational execution and the launch of its new Kinatico Compliance solution.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

Swift TV Ltd has ceased its decade-long monthly subscription services with Mineral Resources, pivoting to a hardware-enabled SaaS model with its flagship Swift TV product. The company is set to deploy over 4,300 screens across 11 sites by March 2026, marking a significant strategic shift.

MONEYME has locked in a $300 million credit card warehouse financing facility with improved pricing, setting the stage for its new credit card product launch in 2026.

Harmoney Corp Limited reported a staggering 742% increase in Cash NPAT for FY25, driven by its new Stellare® 2.0 platform and operational efficiencies. The company reaffirmed its ambitious $12 million profit target for FY26 while unveiling a secured car loan product and securing a major bank debt facility.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

McPherson’s Limited has unveiled a sweeping two-year transformation, streamlining its brand portfolio and adopting a scalable third-party logistics model to drive growth and improve financial stability.